Johnson & Johnson’s Tremfya Approved to Treat Plaque Psoriasis

In July 2017, the US FDA (Food and Drug Administration) approved Johnson & Johnson’s (JNJ) Tremfya (guselkumab) for the treatment of individuals with moderate to severe plaque psoriasis.